| Paper | Authors | Journal | Year | Type |
|---|
| Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide | Wendel D et al. | Journal of pediatric gastroenterology and nutrition | 2026 | Randomized Controlled Trial |
| Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study | Masumoto K et al. | Pediatrics international : official journal of the Japan Pediatric Society | 2026 | Clinical Trial, Phase III |
| Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration | Sturgeon JP et al. | EBioMedicine | 2025 | Randomized Controlled Trial |
| Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial | Chandwe K et al. | Nature communications | 2024 | Randomized Controlled Trial |
| Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis | Micic D et al. | Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition | 2024 | Randomized Controlled Trial |
| Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure | Fifi A et al. | Journal of pediatric gastroenterology and nutrition | 2023 | Clinical Trial, Phase III |
| Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support | Chiba M et al. | Journal of pediatric gastroenterology and nutrition | 2023 | Randomized Controlled Trial |
| Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension | Nakamura S et al. | Surgery today | 2023 | Clinical Trial, Phase III |
| Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study | Yeh DD et al. | Clinical nutrition ESPEN | 2022 | Randomized Controlled Trial |
| Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support | Chen K et al. | Clinical nutrition ESPEN | 2021 | Clinical Trial, Phase III |
| Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study | Jeppesen PB et al. | Clinical nutrition (Edinburgh, Scotland) | 2020 | Randomized Controlled Trial |
| Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure | Chen K et al. | JPEN. Journal of parenteral and enteral nutrition | 2020 | Randomized Controlled Trial |
| Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism | Xiao C et al. | Diabetes, obesity & metabolism | 2019 | Randomized Controlled Trial |
| Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study | Seidner DL et al. | Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition | 2018 | Randomized Controlled Trial |
| Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure | Jeppesen PB et al. | Gastroenterology | 2018 | Randomized Controlled Trial |
| Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome | Iyer KR et al. | JPEN. Journal of parenteral and enteral nutrition | 2017 | Randomized Controlled Trial |
| Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome | Carter BA et al. | The Journal of pediatrics | 2017 | Clinical Trial, Phase III |
| Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide | Fujioka K et al. | JPEN. Journal of parenteral and enteral nutrition | 2017 | Randomized Controlled Trial |
| Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition | Iturrino J et al. | JPEN. Journal of parenteral and enteral nutrition | 2016 | Randomized Controlled Trial |
| A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects | Berg JK et al. | BMC gastroenterology | 2014 | Randomized Controlled Trial |
| Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study | Jeppesen PB et al. | Clinical nutrition (Edinburgh, Scotland) | 2013 | Randomized Controlled Trial |
| Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome | Tappenden KA et al. | Journal of clinical gastroenterology | 2013 | Randomized Controlled Trial |
| Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure | O'Keefe SJ et al. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2013 | Randomized Controlled Trial |
| Pharmacokinetics of teduglutide in subjects with renal impairment | Nave R et al. | European journal of clinical pharmacology | 2013 | Controlled Clinical Trial |
| Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure | Jeppesen PB et al. | Gastroenterology | 2012 | Randomized Controlled Trial |
| Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome | Jeppesen PB et al. | Gut | 2011 | Randomized Controlled Trial |
| Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease | Buchman AL et al. | Inflammatory bowel diseases | 2010 | Randomized Controlled Trial |
| Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects | Marier JF et al. | Journal of clinical pharmacology | 2008 | Randomized Controlled Trial |
| Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients | Jeppesen PB et al. | Gut | 2005 | Clinical Trial |